The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density

Maturitas

Volumn 41, Issue 2, 2002, Pages 143-147

  Gass, Margery ^a   Liu, James ^a   Rebar, Robert W ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE   (United States)

Author keywords

Bone mineral density; Hormone replacement therapy; Postmenopausal women

Indexed keywords

CITRATE CALCIUM; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE EXAMINATION; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; FEMUR NECK; HIP; HORMONE SUBSTITUTION; HUMAN; MEDICAL PRACTICE; POSTMENOPAUSE; SPINE;

BONE DENSITY; CALCIUM CITRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; VITAMIN D;

EQUIDAE;

EID: 0037176793     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(01)00257-2     Document Type: Article

References (27)

1. Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment
2. The effect of estrogen dose on postmenopausal bone loss
3. The effects of estrone (Ogen) on spinal bone density of postmenopausal women
4. Compliance with hormone therapy
5. Compliance of women in taking estrogen replacement therapy
6. Characteristics of women who continue using hormone replacement therapy
7. Hormone Replacement Therapy
8. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
9. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
10. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women
11. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages
12. Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol
13. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium and lipid levels
14. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women
15. Continuous low-dose oestrogen and progestogen hormone replacement therapy: A randomised trial
16. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen
17. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins
18. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
19. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
20. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
21. Monitoring osteoporosis therapy with bone densitometry. Misleading changes and regression to the mean
22. How many women lose bone density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial
23. Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens
24. Personal Perspective on low-dosage estrogen therapy for postmenopausal women
25. Moderation of the daily dose of HRT: Benefits for patients
26. Low-dose unopposed estrogens: Findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period
27. Association between breast cancer and bone mineral density: The Dubbo Osteoporosis Epidemiology Study